# Ironwood Pharmaceuticals Inc: overview IRWD · Nasdaq · CIK 1446847 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/irwd.md) · [Financials](/companies/irwd/financials.md) · [Filings](/companies/irwd/filings.md) · [Insiders](/companies/irwd/insiders.md) Latest reported revenue: [$113.0m](/filings/0001104659-26-091987.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-26-091987). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [91.6](/filings/0001104659-26-020489.md) | [90.5](/filings/0001104659-26-020489.md) | [41.1](/filings/0001104659-26-057110.md) | [85.2](/filings/0001104659-26-091987.md) | [122](/filings/0001104659-26-020489.md) | [47.7](/filings/0001104659-26-020489.md) | [107](/filings/0001104659-26-057110.md) | [113](/filings/0001104659-26-091987.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [28.0%](/filings/0001104659-25-108795.md) | [34.8% d](/filings/0001104659-26-020489.md) | [(70.7%)](/filings/0001104659-26-057110.md) | [53.2%](/filings/0001104659-26-091987.md) | [61.8%](/filings/0001104659-25-108795.md) | [14.3% d](/filings/0001104659-26-020489.md) | [68.1%](/filings/0001104659-26-057110.md) | [70.2%](/filings/0001104659-26-091987.md) | | Net margin | % | [4.0%](/filings/0001104659-26-020489.md) | [2.5%](/filings/0001104659-26-020489.md) | [(90.9%)](/filings/0001104659-26-057110.md) | [27.7%](/filings/0001104659-26-091987.md) | [32.8%](/filings/0001104659-26-020489.md) | [(4.8%)](/filings/0001104659-26-020489.md) | [38.3%](/filings/0001104659-26-057110.md) | [45.4%](/filings/0001104659-26-091987.md) | | Diluted EPS | $ per share | [0.02](/filings/0001104659-26-020489.md) | [0.01](/filings/0001104659-26-020489.md) | [(0.23)](/filings/0001104659-26-057110.md) | [0.14](/filings/0001104659-26-091987.md) | [0.23](/filings/0001104659-26-020489.md) | [(0.01)](/filings/0001104659-26-020489.md) | [0.24](/filings/0001104659-26-057110.md) | [0.31](/filings/0001104659-26-091987.md) | | Free cash flow | $m | [9.9 d](/filings/0001104659-25-108795.md) | [15.2 d](/filings/0001104659-26-020489.md) | [19.9](/filings/0001104659-26-057110.md) | [(15.1) d](/filings/0001104659-26-091987.md) | [47.6 d](/filings/0001104659-25-108795.md) | [74.6 d](/filings/0001104659-26-020489.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [414](/filings/0001558370-24-001275.md) | [411](/filings/0001558370-25-004072.md) | [443](/filings/0001558370-25-004072.md) | [351](/filings/0001104659-26-020489.md) | [296](/filings/0001104659-26-020489.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [56.1%](/filings/0001558370-24-001275.md) | [61.0%](/filings/0001558370-25-004072.md) | [(213.5%)](/filings/0001558370-25-004072.md) | [26.5%](/filings/0001104659-26-020489.md) | [33.3%](/filings/0001104659-26-020489.md) | | Net margin | % | [127.7%](/filings/0001558370-24-001275.md) | [42.6%](/filings/0001558370-25-004072.md) | [(226.4%)](/filings/0001558370-25-004072.md) | [0.3%](/filings/0001104659-26-020489.md) | [8.1%](/filings/0001104659-26-020489.md) | | Diluted EPS | $ per share | [3.21](/filings/0001558370-24-001275.md) | [0.96](/filings/0001558370-25-004072.md) | [(6.45)](/filings/0001558370-25-004072.md) | [0.01](/filings/0001104659-26-020489.md) | [0.15](/filings/0001104659-26-020489.md) | | Free cash flow | $m | [262](/filings/0001558370-24-001275.md) | [274](/filings/0001558370-25-004072.md) | [183](/filings/0001558370-25-004072.md) | [103](/filings/0001104659-26-020489.md) | [127](/filings/0001104659-26-020489.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/irwd/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $74.9m | 17,788,557 | | Added +4,425,627 | | [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $58.7m | 13,932,000 | | Reduced −1,096,000 | | [Sarissa Capital Management LP](/funds/1577524.md) | 2026-06-30 | $38.7m | 9,188,635 | | Unchanged | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $37.1m | 8,809,601 | | Added +1,352,657 | | [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $36.6m | 8,683,803 | | Added +896 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $33.7m | 7,993,226 | | Reduced −67,847 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $27.8m | 6,608,508 | | Added +511,054 | | [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $27.2m | 6,465,921 | | Reduced −1,069,159 | | [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $23.2m | 5,513,355 | | Reduced −1,168,682 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $20.3m | 4,831,657 | | Added +288,135 | ## Recent filings [All 1,404 filings](/companies/irwd/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-16 | 11:30 ET | [8-K](/filings/0001104659-26-116423.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-26-116423 | | 2026-08-06 | 20:07 ET | [10-Q](/filings/0001104659-26-091987.md) | Quarterly report, period 2026-06-30 | 0001104659-26-091987 | | 2026-08-06 | 11:12 ET | [8-K](/filings/0001104659-26-091625.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-091625 | | 2026-06-18 | 20:14 ET | [8-K](/filings/0001104659-26-075730.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-075730 | | 2026-06-15 | 20:05 ET | [8-K](/filings/0001104659-26-074023.md) | 8.01 Other events | 0001104659-26-074023 | | 2026-05-21 | 20:05 ET | [8-K/A](/filings/0001104659-26-065140.md) | 5.02 Departure or appointment of officers or directors | 0001104659-26-065140 | | 2026-05-13 | 12:00 ET | [8-K](/filings/0001104659-26-059814.md) | 5.02 Departure or appointment of officers or directors | 0001104659-26-059814 | | 2026-05-07 | 20:08 ET | [10-Q](/filings/0001104659-26-057110.md) | Quarterly report, period 2026-03-31 | 0001104659-26-057110 | | 2026-05-07 | 11:10 ET | [8-K](/filings/0001104659-26-056656.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-056656 | | 2026-04-28 | 20:06 ET | [DEF 14A](/filings/0001104659-26-050325.md) | Proxy statement, period 2026-06-16 | 0001104659-26-050325 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-020489.md), filed Feb 26, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/8ff5de26-7598-4493-81eb-e46107bd473f) ## About the filer - CIK: 1446847 - Tickers: IRWD - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.